BG
REGN icon

Bellevue Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Bellevue Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.1M Sell
157,291
-121,383
-44% -$82.6M 2.06% 15
2026
Q1 		$215M Buy
278,674
+264,746
+1,901% +$203M 5.12% 3
2025
Q4 		$10.8M Sell
13,928
-1,129
-7% -$767K 0.2% 59
2025
Q3 		$8.47M Sell
15,057
-11,687
-44% -$6.61M 0.18% 65
2025
Q2 		$14M Sell
26,744
-1,779
-6% -$993K 0.31% 58
2025
Q1 		$18.1M Sell
28,523
-2,889
-9% -$1.99M 0.41% 53
2024
Q4 		$22.4M Buy
31,412
+4,636
+17% +$3.89M 0.43% 57
2024
Q3 		$28.1M Sell
26,776
-5,521
-17% -$6.14M 0.46% 64
2024
Q2 		$33.9M Buy
32,297
+25,220
+356% +$24.4M 0.55% 52
2024
Q1 		$6.81M Sell
7,077
-3,632
-34% -$3.45M 0.1% 92
2023
Q4 		$9.41M Sell
10,709
-4,230
-28% -$3.48M 0.14% 88
2023
Q3 		$12.3M Sell
14,939
-1,388
-9% -$1.09M 0.2% 84
2023
Q2 		$11.7M Buy
16,327
+1,011
+7% +$779K 0.17% 91
2023
Q1 		$12.6M Sell
15,316
-362
-2% -$273K 0.18% 90
2022
Q4 		$11.3M Sell
15,678
-1,711
-10% -$1.26M 0.15% 95
2022
Q3 		$12M Sell
17,389
-338
-2% -$213K 0.17% 96
2022
Q2 		$10.5M Sell
17,727
-72,553
-80% -$47.2M 0.15% 104
2022
Q1 		$63.1M Sell
90,280
-2,780
-3% -$1.76M 0.73% 47
2021
Q4 		$58.8M Sell
93,060
-13,350
-13% -$8.21M 0.61% 55
2021
Q3 		$64.4M Buy
106,410
+750
+0.7% +$466K 0.65% 49
2021
Q2 		$59M Buy
105,660
+69,860
+195% +$35.4M 0.58% 59
2021
Q1 		$16.9M Buy
35,800
+8,100
+29% +$3.94M 0.18% 105
2020
Q4 		$13.4M Buy
27,700
+7,700
+39% +$4.16M 0.15% 110
2020
Q3 		$11.2M Sell
20,000
-3,100
-13% -$1.88M 0.15% 105
2020
Q2 		$14.4M Buy
23,100
+4,000
+21% +$2.27M 0.2% 93
2020
Q1 		$9.33M Sell
19,100
-2,900
-13% -$1.2M 0.18% 90
2019
Q4 		$8.26M Buy
+22,000
New +$7.4M 0.13% 101
2019
Q2 		– Sell
-20,400
Closed -$8.38M – 213
2019
Q1 		$8.38M Buy
20,400
+5,200
+34% +$2.14M 0.46% 62
2018
Q4 		$5.68M Sell
15,200
-10,280
-40% -$3.76M 0.37% 64
2018
Q3 		$10.3M Buy
25,480
+8,220
+48% +$3.13M 0.65% 49
2018
Q2 		$5.96M Sell
17,260
-10,120
-37% -$3.17M 0.51% 53
2018
Q1 		$9.43M Sell
27,380
-420
-2% -$146K 0.93% 42
2017
Q4 		$10.5M Sell
27,800
-2,400
-8% -$972K 1.09% 36
2017
Q3 		$13.5M Buy
30,200
+2,100
+7% +$999K 1.41% 23
2017
Q2 		$13.8M Sell
28,100
-1,200
-4% -$525K 1.63% 18
2017
Q1 		$11.4M Sell
29,300
-3,000
-9% -$1.11M 1.51% 25
2016
Q4 		$11.9M Sell
32,300
-5,700
-15% -$2.17M 2.43% 12
2016
Q3 		$15.3M Buy
38,000
+8,000
+27% +$3.21M 2.76% 7
2016
Q2 		$10.5M Sell
30,000
-2,400
-7% -$924K 1.97% 14
2016
Q1 		$11.7M Buy
+32,400
New +$13.4M 2.12% 12

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bellevue Group's REGN Position: Q2 2026 in Review

Bellevue Group reduced its Regeneron Pharmaceuticals (REGN) stake by 44% in Q2 2026, selling an estimated $82.6M and leaving 157,291 shares worth $98.1M. The position accounts for 2.06% of the portfolio, ranked #15.

Bellevue Group first reported a position in REGN in Q1 2016 and has held it in 40 quarters since. The position peaked at $215M in Q1 2026. 1,204 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Bellevue Group held 157,291 shares of Regeneron Pharmaceuticals worth $98.1M as of Q2 2026.
  • Bellevue Group sold 121,383 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $82.6M.
  • Regeneron Pharmaceuticals made up 2.06% of Bellevue Group's portfolio in Q2 2026, its #15 holding.
  • Bellevue Group first reported a position in Regeneron Pharmaceuticals in Q1 2016 and has held it in 40 quarters since.
  • Bellevue Group's Regeneron Pharmaceuticals position peaked at $215M in Q1 2026.
  • 1,204 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.